

Service Profiles

Sue Knights Senior Information Manager NCIN/NPR



Profiles - Rationale



Service profiles:

- Benchmark and assess
- NHS Trust / multi-disciplinary team (MDT) based
- Assist clinical teams to reflect on outcomes
- Assist the commissioners of cancer services to
 - understand the variation across the MDT's (local service) for both patient experience and patient care.
- Indicators included have been
 - discussed with commissioners and MDT's as being important and form the basis for objective dialogue about clinical practice and service delivery.

Profiles - Process



Using information to improve quality & choice

Service profiles:

- Developed from similar Breast/Colorectal/ Lung profiles (published Dec 2011, Feb 2013, June 2013)
- Based on latest nationally available data
 - cancer registration, CWT, NLCA, CPES, HES, Peer Review
- Part generic, part specialist indicators.
- Specialist indicators largely drawn from National audits
- Indicators also incorporate Clinical Lines of Enquiry

Profiles - structure




Using information to improve quality & choice

NCIN / PHE KIT team (formally Thames Cancer Registry) co-production

Hosted in the Cancer Commissioning Toolkit –

Public view – open access

Professional view - access registration required



www.cancertoolkit.co.uk

Profiles...



			1		Percenta	ge or rate		Tr	ust rate or percentage compared to Eng	and	l	
Section	#	Indicator	No. of patients/ cases or value	Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range	High- est	Source	Period
	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				207	41	• •	588	NCDR	2010
Size	2	Number of NLCA patients - lung cancer	329				191	1	•	585	NLCA	2011
	3	Number of NLCA patients - mesothelioma	11				10	0	•0	31	NLCA	2011
	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%	•	75%	NCDR	2010
(0	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%	•	100%	NCDR	2010
Demographics (based on newly gnosed patients, 2010)	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%	•	46%	NCDR	2010
hic ewl nts,	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%	→ 0	34%	NCDR	2010
rap on n atiei	8	Male patients (from #1)	161	53%	47%	58%	55%	43%	0 •	72%	NCDR	2010
ed o	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%	•	100%	NLCA	2011
bas bas	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%	• •	68%	NLCA	2011
co co	11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned	36	13%	9%	17%	14%	4%	0	30%	NLCA	2011
ਰ	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned	167	58%	53%	64%	62%	13%	•	80%	NLCA	2011
	13	Proportion of patients (from #2) with a Performance Status assigned	286	87%	83%	90%	89%	2%	0	100%	NLCA	2011
	14	Peer review: Does the specialist team have full membership? (3)	SA	Yes							NCPR	2010/11
Specialist	15	Peer review: Proportion of peer review indicators met	SA	85%			89%				NCPR	2010/11
Team	16	Peer review: are there immediate risks? (4)	SA	No							NCPR	2010/11
ream	17	Peer review: are there serious concerns? (4)	SA	No							NCPR	2010/11
	18	Number and proportion of patients (from #2) seen by CNS (5)	206	63%	57%	68%	79%	0%	◆	100%	NLCA	2011
	19	Number of urgent GP referrals for suspected cancer	406				293	0	•••	853	CWT	2010/11
	20	Number and proportion of patients (from #2) with confirmed NSCLC	184	56%	52%	60%	62%	0%	•	93%	NLCA	2011
Throughput and	21	Number and proportion of patients (from #2) with confirmed SCLC	40	12%	9%	16%	12%	0%	o	100%	NLCA	2011
pathology	22	Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS	21	11%	8%	17%	19%	0%	○ ♦	79%	NLCA	2011
patriology	23	Number and proportion of patients (from #2) with histological confirmation of diagnosis	228	69%	64%	74%	77%	52%	◆	100%	NLCA	2011
	24	Estimated proportion of tumours with emergency presentations [experimental]	94	47%	40%	54%	37%	2%	♦ 0	97%	HES	2011
	25	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks	135	96%	92%	98%	97%	88%	O	100%	CWT	2012/13 Q2
	26	Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer	15	73%	52%	87%	80%	0%	0.	100%	CWT	2012/13 Q2
Waiting times	27	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	103	25%	21%	30%	24%	4%	•••	46%	CWT	2011/12
	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]	34	25%	19%	33%	39%	0%	• •	76%	CWT	2011/12
	29	Q2 2012/13: First treatment began within 31 days of decision to treat	14	100%	78%	100%	99%	91%	↑ •	100%	CWT	2012/13 Q2
	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	47%	58%	60%	36%	0 •	100%	NLCA	2011
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC	50	17%	13%	22%	16%	0%	•0	38%	NLCA	2011
Drastics	32	No. and proportion resected of patients (from #2) with confirmed NSCLC	48	26%	20%	33%	21%	0%	• O	45%	NLCA	2011
Practice	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC ,with stage I and II disease	40	48%	38%	59%	53%	0%	○ ◆	100%	NLCA	2011
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	27	68%	52%	80%	68%	0%	O	100%	NLCA	2011
	35	No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy	28	58%	44%	71%	55%	0%	•	100%	NLCA	2011
Outcome	36	First outpatient appointments and proportion of all outpatient appointments	23,053	41%	41%	41%	32%	15%	•	68%	PBR SUS	2011/12
Outcomes and Recovery	37	NLCA: Median survival in days and adjusted hazard ratio for mortality	176	0.95	0.82	1.11	1.0	0.57	•	1.49	NLCA	2011
and Recovery	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	34%	1.43	0.97	2.11	1.0	0.40	• •	2.67	NLCA	2011
Patient	39	Patients surveyed & % reporting always being treated with respect & dignity (6)	13	n/a			83%	66%	.	100%	CPES	2011/12
Experience -	40	N		n/a				0%		78%	CPES	2011/12
CPES (8)	41	Number of survey questions and % of those questions scoring red and green (7) With the content of the conten	1 0	n/a				0%	1	69%	CPES	2011/12

Profiles... rationale



					Percenta	ge or rate		Tr	ust rate or percentage compared to Eng	land	Ī	
Section	#	Indicator	No. of patients/ cases or value	Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range	High- est	Source	Period
	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				207	41	→ •	588	NCDR	2010
Size	2	Number of NLCA patients - lung cancer	329				191	1	•	585	NLCA	2011
	3	Number of NLCA patients - mesothelioma	11				10	0	* O	31	NLCA	2011
	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%	•	75%	NCDR	2010
6	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%		100%	NCDR	2010
s y 2010)	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%	○	46%	NCDR	2010
Demographics (based on newly nosed patients, 2	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%	→ ○	34%	NCDR	2010
rap on n	8	Male patients (from #1)	161	53%	47%	58%	55%	43%	• •	72%	NCDR	2010
o pa	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%	★	100%	NLCA	2011
Dem (bas nose	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%	• •	68%	NLCA	2011
agn (11	Number a			-				•	_	NLCA	2011
₽	12	Number a								_	NLCA	2011
	13	Proportion • Assess and benchmar	kav	vid	o ra	naa	Λf	iní	formation at	_	NLCA	2011
	14	Peer revie A33C33 and Dentilinar	n a v	VIU	c Ia	uye	UI		ioimation at		NCPR	2010/1
	15	Peer revie									NCPR	2010/1
Specialist	16	Peer revie									NCPR	2010/1
Team	17	Peer revie or conjugation lovel									NCPR	2010/1
	18	Peer revit organisation level								_		
											NLCA	2011
	19									-		_
	19 20	Number c								-	CWT	2010/1
0 1		Number c Number a		201	2010	L _£	0 10	.	ganiaatian	-	CWT NLCA	2010/1 2011
and	20 21	Number c Number a	sse	ssn	nen	t of	an (or	ganisation	- - -	CWT NLCA NLCA	2010/1 2011 2011
0 1	20 21 22	Number a Num	sse	ssn	nen	t of	an	or	ganisation	-	CWT NLCA NLCA NLCA	2010/1 2011 2011 2011
and	20 21 22 23	Number a	sse	ssn	nen	t of	an	or	ganisation	- - - -	CWT NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011
and	20 21 22 23 24	Number c Number a Number a Number a Number a Sumber a Estimatec Number a Estimatec	sse	ssn	nen	t of	an	or	ganisation	-	CWT NLCA NLCA NLCA NLCA HES	2010/1 2011 2011 2011 2011 2011
	20 21 22 23 24 25	Number a Number a Number a Summater Sum	ISS e :	ssn	nen	t of	an (or	ganisation	- - - - -	CWT NLCA NLCA NLCA NLCA HES CWT	2010/1 2011 2011 2011 2011 2011 2011 201
and pathology	20 21 22 23 24 25 26	Number a Number a Number a Number a Sumber a Sum							ganisation	46%	CWT NLCA NLCA NLCA NLCA NLCA CWT CWT	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13
and pathology	20 21 22 23 24 25 26 27	Number a Number a Number a Number a Number a Number a Stimatec Q2 2012/ Q2 2012/ Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	103	25%	21%	30%	24%	4%	ganisation	46%	CWT NLCA NLCA NLCA NLCA HES CWT CWT	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1
and pathology	20 21 22 23 24 25 26 27 28	Number c Number a Number a Number a Number a Number a Stimatec O2 2012/ Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer (experimental)	103	25% 25%	21% 19%	30% 33%	24% 39%	4% 0%	ganisation	76%	CWT NLCA NLCA NLCA NLCA NLCA CWT CWT CWT	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1
and pathology	20 21 22 23 24 25 26 27 28 29	Number a Number a Number a Number a Number a Sumber a Sum	103 34 14	25% 25% 100%	21% 19% 78%	30% 33% 100%	24% 39% 99%	4% 0% 91%	•	76% 100%	CWT NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1 2011/1 2012/13
and pathology	20 21 22 23 24 25 26 27 28 29	Number a Number a Number a Number a Number a Stimatec Q2 2012/ Q2 2012/ Q2 2012/ Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	103 34 14 174	25% 25% 100% 53%	21% 19% 78% 47%	30% 33% 100% 58%	24% 39% 99% 60%	4% 0% 91% 36%	ganisation	76% 100% 100%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1 2012/13 2011/1
and pathology	20 21 22 23 24 25 26 27 28 29 30 31	Number a Number a Number a Number a Number a Number a Estimatec Q2 2012/ Q2 2012/ Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC	103 34 14 174 50	25% 25% 100% 53% 17%	21% 19% 78% 47% 13%	30% 33% 100% 58% 22%	24% 39% 99% 60% 16%	4% 0% 91% 36% 0%	• • •	76% 100% 100% 38%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1
and pathology	20 21 22 23 24 25 26 27 28 29 30 31 32	Number a Sestimatec Q2 2012/ Q2 2012/ Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed NSCLC	103 34 14 174 50	25% 25% 100% 53% 17% 26%	21% 19% 78% 47% 13% 20%	30% 33% 100% 58% 22% 33%	24% 39% 99% 60% 16% 21%	4% 0% 91% 36% 0%	• • • • • • • • • • • • • • • • • • • •	76% 100% 100% 38% 45%	CWT NLCA NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1
and pathology	20 21 22 23 24 25 26 27 28 29 30 31 32 33	Number a Num	103 34 14 174 50 48	25% 25% 100% 53% 17% 26% 48%	21% 19% 78% 47% 13% 20% 38%	30% 33% 100% 58% 22% 33% 59%	24% 39% 99% 60% 16% 21% 53%	4% 0% 91% 36% 0% 0%	• • •	76% 100% 100% 38% 45% 100%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2011 201
and pathology	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	Number a Num	103 34 14 174 50 48 40 27	25% 25% 100% 53% 17% 26% 48% 68%	21% 19% 78% 47% 13% 20% 38% 52%	30% 33% 100% 58% 22% 33% 59% 80%	24% 39% 99% 60% 16% 21% 53% 68%	4% 0% 91% 36% 0%	• • • • • • • • • • • • • • • • • • • •	76% 100% 100% 38% 45% 100%	CWT NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2011 201
and pathology /aiting times	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35	Number a Num	103 34 14 174 50 48 40 27 28	25% 25% 100% 53% 17% 26% 48% 68% 58%	21% 19% 78% 47% 13% 20% 38% 52% 44%	30% 33% 100% 58% 22% 33% 59% 80% 71%	24% 39% 99% 60% 16% 21% 53% 68% 55%	4% 0% 91% 36% 0% 0% 0%		76% 100% 100% 38% 45% 100% 100%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2011 201
and pathology laiting times Practice Outcomes	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36	Number a Num	103 34 14 174 50 48 40 27 28 23,053	25% 25% 100% 53% 17% 26% 48% 68% 58% 41%	21% 19% 78% 47% 13% 20% 38% 52% 44%	30% 33% 100% 58% 22% 333% 59% 80% 711%	24% 39% 99% 60% 21% 53% 68% 55% 32%	4% 0% 91% 36% 0% 0% 0% 0%		76% 100% 100% 38% 45% 100% 100% 68%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA PBR SUS	2010/1 2011 2011 2011 2011 2011 2011 201
and pathology /aiting times Practice Outcomes	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36	Number a Num	103 34 14 174 50 48 40 27 28 23,053	25% 25% 100% 53% 17% 26% 48% 68% 58% 41%	21% 19% 78% 47% 133% 20% 38% 52% 44% 0.82	30% 33% 100% 58% 22% 33% 59% 80% 71% 41%	24% 39% 99% 60% 16% 21% 53% 68% 55% 32%	4% 0% 91% 36% 0% 0% 0% 0% 15%		76% 100% 100% 38% 45% 100% 100% 100%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2011 201
and pathology /aiting times Practice Outcomes and Recovery	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	Number a Num	103 34 14 174 50 48 40 27 28 23,053 176 34%	25% 25% 100% 53% 17% 26% 48% 68% 58% 41% 0.95	21% 19% 78% 47% 13% 20% 38% 52% 44% 0.82	30% 33% 100% 58% 22% 333% 59% 80% 711%	24% 39% 99% 60% 16% 21% 53% 68% 55% 32% 1.0	4% 0% 91% 36% 0% 0% 0% 0% 15% 0.57		76% 100% 100% 38% 45% 100% 100% 68% 1.49 2.67	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2011 201
and pathology /aiting times Practice Outcomes and Recovery Patient	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36	Number a Num	103 34 14 174 50 48 40 27 28 23,053	25% 25% 100% 53% 17% 26% 48% 68% 58% 0.95 1.43	21% 19% 78% 47% 13% 20% 38% 52% 44% 0.82	30% 33% 100% 58% 22% 33% 59% 80% 71% 41%	24% 39% 99% 60% 16% 21% 53% 68% 55% 32%	4% 0% 91% 36% 0% 0% 0% 0% 057 0.57 0.40		76% 100% 100% 38% 45% 100% 100% 68% 1.49 2.67	CWT NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1: 2011 2011 2011 2011 2011 2011 2011 20
and pathology /aiting times Practice Outcomes nd Recovery	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	Number a Num	103 34 14 174 50 48 40 27 28 23,053 176 34%	25% 25% 100% 53% 17% 26% 48% 68% 58% 41% 0.95	21% 19% 78% 47% 13% 20% 38% 44% 41% 0.82 0.97	30% 33% 100% 58% 22% 33% 59% 80% 71% 41%	24% 39% 99% 60% 16% 21% 53% 68% 55% 32% 1.0	4% 0% 91% 36% 0% 0% 0% 0% 15% 0.57		76% 100% 100% 38% 45% 100% 100% 68% 1.49 2.67	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2011 201

Profile anatomy



					Percenta	ge or rate		Tru	ust rate or percentage compared to Eng	land		
Section		Indicator	patients/ cases or value	Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range	High- est	Source	Period
	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				20	41	• •	588	NCDR	2010
Size	2	Number of NLCA patients - lung cancer	329				19	1	• 0	585	NLCA	2011
	3	Number of NLCA patients - mesothelioma	11				1	0	•	31	NLCA	2011
	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%		75%	NCDR	2010
6	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%		100%	NCDR	201
s y 2010)	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%	○ ◆	46%	NCDR	201
Demographics (based on newly diagnosed patients, 20	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%	→ ○	34%	NCDR	201
rap on n	8	Male patients (from #1)	161	53%	47%	58%	55%	43%	0 •	72%	NCDR	201
ed o	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%	(A)	100%	NLCA	201
bas lose	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%	• •	68%	NLCA	201
agn (11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned	36	13%	9%	17%	14%	4%	O.	30%	NLCA	201
ъ	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned	167	58%	53%	64%	62%	13%	Q.	80%	NLCA	201
	13	Proportion of patients (from #2) with a Performance Status assigned	286	87%	83%	90%	89%	2%	O	100%	NLCA	201
	14	Peer review: Doe									NCPR	2010/
Specialist Team		Peer review: are Peer R	-		mbe	_			Spine chart &	S	our	ces
		Number of Area		rate	es, a	and	9%		repare of date	(
h	19 20	Number of urgeni	_		•		9% 2% 2%		range of data	14		
hroughput	19 20 21	Number and prop Number and prop (41)	_		•		99 29 29 29		range of data	(<u>k</u> <u>K</u> 16070	Da	tes
and	19 20 21 22	Number and prop	C		es, a para		99 29 29 29 99		range of data	(<u>!</u> ! <u>!</u> 16070		tes
and	19 20 21 22 23	Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis	C(om 69%	para 64%	ator:	99 779	0% 0% 52%	•	160% 79%	NLCA NLCA	201 201 201
and	19 20 21 22 23 24	Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental]	228 94	69% 47%	para 64% 40%	74% 54%	9% 77% 37%	U% 0%	•	(k <u>k</u> 1607 79%	NLCA	201 201 201
and	19 20 21 22 23 24 25	Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks	228 94 135	om 69%	para 64% 40% 92%	74% 54% 98%	99 779 379 979	0% 0% 52%	• • • • • • • • • • • • • • • • • • •	160% 79%	NLCA NLCA	201 201 201 201
and athology	19 20 21 22 23 24 25 26	Number and prop Number and prop Number and prop Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer	228 94 135	69% 47% 96% 73%	64% 40% 92% 52%	74% 54% 98% 87%	99 779 379 979 809	0% 0% 52% 2%	•	100% 79% 100% 97% 100% 100%	NLCA NLCA HES CWT	201 201 201 201 2012/1: 2012/1:
and athology	19 20 21 22 23 24 25 26 27	Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] 02 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks 02 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	228 94 135 15	69% 47% 96% 73% 25%	64% 40% 92% 52% 21%	74% 54% 98% 87% 30%	9% 77% 37% 97% 80% 24%	0% 0% 52% 2% 88%	• • • • • • • • • • • • • • • • • • •	79% 100% 97% 100% 100% 46%	NLCA NLCA HES CWT	201 201 201 201 2012/1: 2012/1:
and athology	19 20 21 22 23 24 25 26 27 28	Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of turnours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental]	228 94 135 15 103 34	69% 47% 96% 73% 25% 25%	64% 40% 92% 52% 21% 19%	74% 54% 98% 87% 30% 33%	9% 77% 37% 97% 80% 24% 39%	0% 0% 52% 2% 88% 0%	• • • • • • • • • • • • • • • • • • •	100% 79% 100% 97% 100% 100%	NLCA NLCA NLCA CWT CWT CWT	201 201 201 201 2012/1: 2012/1: 2011/1
and athology	19 20 21 22 23 24 25 26 27 28	Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] 02 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks 02 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	228 94 135 15 103 34	69% 47% 96% 73% 25% 25% 100%	64% 40% 92% 52% 21% 19% 78%	74% 54% 98% 87% 30% 33% 100%	9% 77% 37% 97% 80% 24% 39% 99%	0% 0% 52% 2% 88% 0% 4%	• • • • • • • • • • • • • • • • • • •	79% 100% 97% 100% 100% 46%	NLCA NLCA NLCA HES CWT CWT CWT CWT	2011 2012/1 2012/1 2012/1 2012/1 2011/1 2012/1
and athology	19 20 21 22 23 24 25 26 27 28 29 30	Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Oz 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Oz 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer (experimental] Oz 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	228 94 135 15 103 34 14	69% 47% 96% 73% 25% 25% 100%	64% 40% 92% 52% 21% 19% 78% 47%	74% 54% 98% 87% 30% 33% 100%	9% 77% 37% 97% 80% 24% 39% 99% 60%	0% 0% 52% 2% 88% 0% 4% 0% 91% 36%	• • • • • • • • • • • • • • • • • • •	79% 100% 97% 100% 100% 100% 46% 76% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA	201 201 201 2012/1: 2012/1: 2011/1: 2011/1: 2012/1: 2012/1:
and athology	19 20 21 22 23 24 25 26 27 28 29 30 31	Number and prop Number and propo Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC	228 94 135 15 103 34 14 174 50	69% 47% 96% 73% 25% 25% 100% 53%	64% 40% 92% 52% 21% 19% 78% 47%	74% 54% 98% 87% 30% 100% 58%	99 779 379 979 809 249 399 999 609 169	0% 0% 52% 2% 88% 0% 4% 0% 91%	•	100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT	201 201 201 2012/1: 2012/1: 2011/1: 2011/1: 2012/1: 2012/1:
and athology iting times	19 20 21 22 23 24 25 26 27 28 29 30 31 32	Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] C2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks C2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer (experimental] C2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed NSCLC	228 94 135 15 103 34 14 174 50	69% 47% 96% 25% 25% 100% 53% 17% 26%	64% 40% 92% 52% 21% 19% 47% 47% 13%	74% 54% 98% 87% 30% 33% 100% 58% 22%	99 779 379 979 809 249 399 999 609 169 219	0% 52% 2% 88% 0% 4% 0% 91% 36% 0%		100% 100% 97% 100% 97% 100% 100% 100% 100% 100% 100% 100% 100%	NLCA NLCA HES CWT CWT CWT CWT CWT CNT CWT NLCA NLCA NLCA	201 201 201 2012/1: 2012/1: 2011/1 2011/1 2012/1: 201 201 201 201 201
and athology iting times	19 20 21 22 23 24 25 26 27 28 29 30 31 32 33	Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease	228 94 135 15 103 34 14 174 50 48	69% 47% 96% 25% 25% 100% 53% 17% 48%	64% 40% 92% 52% 21% 19% 78% 47% 47% 20% 38%	74% 54% 98% 87% 30% 33% 100% 58% 22% 33% 59%	99 779 379 979 809 249 399 999 609 169 219 539	0% 52% 2% 88% 0% 4% 91% 36% 0% 0%	•	79% 100% 97% 100% 97% 100% 46% 76% 100% 38% 45% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA	201 201 201 2012/1: 2012/1: 2011/ 2011/ 2012/1: 201 201 201 201 201 201 201 201 201 201
and athology iting times	19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	Number and prop Number and propo Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Oz 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Oz 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Oz 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	228 94 135 15 103 34 14 174 50 48 40	69% 47% 96% 73% 25% 25% 100% 53% 17% 26% 48%	92% 52% 21% 19% 47% 13% 20% 38% 52%	74% 54% 98% 87% 30% 58% 22% 33% 80%	9% 77% 37% 97% 80% 24% 39% 99% 60% 16% 21% 53% 68%	0% 52% 2% 88% 0% 4% 91% 36% 0% 0%		100 / 100 /	NLCA NLCA NLCA CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA	2011 2011 2012/1: 2012/1: 2011
and athology iting times	19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35	Number and prop Number and propotion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed NSCLC No. and proportion of patients (from #2), excluding confirmed SCLC with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	228 94 135 15 103 34 14 174 50 48 40 27	69% 47% 96% 73% 25% 25% 100% 53% 48% 68% 58%	92% 52% 21% 19% 47% 47% 47% 20% 38% 52% 44%	74% 54% 98% 87% 30% 33% 58% 22% 33% 71%	99 779 379 979 809 249 399 999 609 169 219 539 689	0% 52% 2% 88% 0% 4% 0% 91% 36% 0% 0% 0%		100% 100% 100% 100% 100% 100% 100% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA	201 201 201 2012/1: 2012/1: 2011/1 2011/1 2011/1 2011/1 2011 201 201 201 201 201 201 201 201 2
and athology iting times	19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36	Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Oz 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Oz 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Oz 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed NSCLC No. and proportion of patients (from #2) with confirmed SCLC with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and prop. of patients (from #2) with stage IIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy First outpatient appointments and proportion of all outpatient appointments	228 94 135 15 103 34 14 174 50 48 40 27 28 23,053	69% 47% 96% 25% 25% 100% 53% 17% 26% 48% 68% 58%	64% 40% 92% 52% 21% 19% 78% 47% 38% 52% 44% 41%	74% 544% 98% 87% 30% 33% 100% 100% 59% 80% 71% 41%	9% 77% 37% 97% 80% 24% 39% 99% 60% 16% 21% 53% 68%	0% 52% 2% 88% 0% 4% 91% 36% 0% 0% 0% 0%		100% 79% 100% 97% 100% 46% 76% 100% 38% 45% 100% 100% 68%	NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA PBR SUS	2011/12 2011/12 2012/13 2012/13 2011/12 2011/12 2011/12 2011/12 2011/12 2011/12 2011/12 2011/12 2011/12 2011/12
and athology iting times	19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37	Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] C2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks C2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer (experimental] C2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed SCLC, with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy First outpatient appointments and proportion of all outpatient appointments NLCA: Median survival in days and adjusted hazard ratio for mortality	228 94 135 15 103 34 14 174 50 48 40 27 28 23,053	69% 47% 96% 25% 25% 100% 53% 48% 68% 68% 58%	64% 40% 52% 52% 21% 19% 78% 47% 13% 20% 38% 52% 444% 0.82	74% 544% 887% 30% 33% 100% 558% 22% 33% 59% 80% 71,111	99 779 379 979 809 249 399 999 609 169 219 539 689	0% 52% 2% 88% 0% 4% 0% 36% 0% 0% 0% 0% 0%		100 / 79% 100 / 79% 100 / 97% 100 /	NLCA NLCA HES CWT	2011/12 2011/12 2012/13 2012/13 2011/12 2011/12 2011/12 2011 2011 2011
and athology iting times	19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed NSCLC No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients and proportion of all outpatient appointments NLCA: Median survival in days and adjusted hazard ratio for mortality NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	228 94 135 15 103 34 14 174 50 48 40 27 28 23,053 176 34%	69% 47% 96% 73% 25% 100% 53% 48% 68% 58% 41% 0.95	64% 40% 92% 52% 21% 19% 78% 47% 38% 52% 44% 0.82	74% 544% 887% 30% 33% 100% 558% 22% 33% 59% 80% 71,111	99 779 379 979 809 249 399 999 609 169 211 539 688 559 329 1.1	0% 52% 2% 88% 0% 4% 91% 36% 0% 0% 0% 0%		100% 100% 100% 100% 100% 100% 100% 100%	NLCA NLCA NLCA NLCA CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	201 201 2012/13 2012/13 2012/13 2012/13 2011/2 2012/13 201 201 201 201 201 201 201 201 201 201
and athology	19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	Number and prop Number and propotrion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Oz 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Oz 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cance rexperimental] Oz 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and prop. of patients (from #2) with confirmed SCLC receiving chemotherapy No. and prop. of patients (from #2) with confirmed SCLC receiving chemotherapy No. and prop. of patients (from #2) with confirmed SCLC receiving chemotherapy First outpatient appointments and proportion of all outpatient appointments NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year Patients surveyed & % reporting always being treated with respect & dignity (6)	228 94 135 15 103 34 14 174 50 48 40 27 28 23,053	69% 47% 96% 25% 25% 100% 53% 48% 68% 68% 58%	64% 40% 92% 52% 21% 19% 78% 47% 38% 52% 44% 0.82	74% 544% 887% 30% 33% 100% 558% 22% 33% 59% 80% 71,111	99 779 379 979 809 249 399 999 609 169 219 539 689	0% 52% 2% 88% 0% 4% 0% 91% 36% 0% 0% 0% 0% 0% 0%		100% 97% 100% 97% 100% 100% 46% 76% 100% 38% 45% 100% 100% 68% 1.49 2.67	NLCA NLCA NLCA HES CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	201, 201, 201, 2012/13, 2012/13, 2011/1, 2011/1, 2011,
and athology iting times Practice	19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC No. and proportion of patients (from #2), excluding confirmed SCLC, with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy First outpatient appointments and proportion of all outpatient appointments NLCA: Median survival in days and adjusted hazard ratio for mortality NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year Patients surveyed & % reporting always being treated with respect & dignity (6)	228 94 135 15 103 34 14 174 50 48 40 27 28 23,053 176 34%	69% 47% 96% 73% 25% 100% 53% 48% 68% 58% 41% 0.95	64% 40% 92% 52% 21% 19% 78% 47% 38% 52% 44% 0.82	74% 544% 887% 30% 33% 100% 558% 22% 33% 59% 80% 71,111	99 779 379 979 809 249 399 999 609 169 211 539 688 559 329 1.1	0% 52% 2% 88% 0% 91% 36% 0% 0% 0% 0% 0%		100% 100% 100% 100% 100% 100% 100% 100%	NLCA NLCA NLCA NLCA CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2011/ 2011/ 2012/13 2012/13 2012/13 2011/

Profile anatomy



												_	
						Percenta	age or rate		Tre	ust rate or percentage compared to E	ngland		
Section	#	Indicator		No. of patients/ cases or value	Trust	Lower 95% confidence limit		England	Low- est	Range	High- est	Source	Period
	1	Number of newly diagnosed lung cancer patients per year, 2010 [_							* •	588	NCDR	2010
Size	2	Number of NLCA patients - lung cancer	Size – no.	nati	ion:	te d	iaar	106	ha	•	585	NLCA	2011
	3	Number of NLCA patients - mesothelioma		. pati		is u	iagi	103	Cu	* O	31	NLCA	2011
	4	Patients (Irom #1) aged 70*		100	02/0	, , ,	0 017	0 0170	JJ 70		/5%	NCDR	2010
aphics newly ients, 2010)	5	Patients (from #1) with recorded ethnicity		l 295	6 I 97%	ol 94%	%I 98%	93%	66%		100%	NCDR	2010
ics vly s, 20	6	Patients (from #5) with recorded ethnicity which is not White-British Patients (from #1) who are Income Deprived (2)	- Dation	4 44			ء الما ما	9	0%		46%	NCDR NCDR	2010
nev nev ients	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Male patients (from #1)	Patier	it ae	mo	ara	pnic	;s :	43%		34% 72%	NCDR	2010 2010
d on pat	9	Number and proportion of patients (from #2) with a stage assigned					•	,	36%		100%	NLCA	2010
Demographics (based on newly gnosed patients, 20	10	Number and proportion of patients, (norm #2) with a stage assigned Number and proportion of patients, excluding SCLC, with stage I or II	assign (inclu	idin/	n ei	and	2/PS	2	10%		68%	NLCA	2011
a) gua	11	Number and proportion of patients, excluding SCLC, with a stage IIIA	assign	adını	y Si	aye	<i>,</i> ,, ,	ا ا	4%	0	30%	NLCA	2011
<u>a</u>	12	Number and proportion of patients, excluding SCLC, with a stage IIIB		l 167	7 i 58%	53%	64%	62%	13%	0	80%	NLCA	2011
	13	Proportion of nationts (from #2) with a Performance Status assigned		286	87%	83%	90%	89%	2%	0	100%	NI CA	2011
	14	Peer review: Does the specialist team have full membershin? (3)		I 9A	Vac	,				I		NCPR	2010/1
													00404
Considiat	15	Pe A	D D	• .								NCPR	2010/1
Specialist	15 16	Specialist team -	Peer Rev	iew d	con	cer	ns a	and	CI	VS coverage		NCPR	
Specialist Team	15 16 17	Specialist team –	Peer Rev	iew (con	cer	ns a	and	CI	NS coverage			2010/1 2010/1
	15 16 17 18	Number and proportion of nationts (from #2) seen by CNS (5)	Peer Rev	iew (con	cer	ns a	and	CI	NS coverage	1100%	NCPR NCPR NLCA	2010/1 2010/1 2011
	15 16 17 18	Number and proportion of nations (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer	Peer Rev	iew (CON	cer	ns a	and 293 293	CI	NS coverage	853	NCPR NCPR NLCA CWT	2010/1 2010/1 2011 2010/1
Team	15 16 17 18 19 20	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent CP referrals for suspected cancer Number and proportion of pati		406	63%	57%	/AL 68º/	293	0%		853 93%	NCPR NCPR NLCA CWT NLCA	2010/1 2010/1 2011 2010/1 2011
Team Throughput and	15 16 17 18 19 20 21	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent CP referrals for suspected cancer Number and proportion of pati		406	63%	57%	/AL 68º/	293	0%		100%	NCPR NCPR NLCA CWT NLCA NLCA	2010/1 2010/1 2011/1 2010/1 2011 2011
Team Throughput and	21 22	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Number and proportion of pati Number and proportion of pati		406	63%	57%	/AL 68º/	293	0%		100% 79%	NCPR NCPR NLCA CWT NLCA NLCA NLCA	2010/1 2010/1 2011/1 2010/1 2011 2011 20
Team Throughput and	15 16 17 18 19 20 21 22 23 24	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati	ut and pa	406	63%	/ - F	patie	293	0%		100%	NCPR NCPR NLCA CWT NLCA NLCA NLCA NLCA	2010/1 2010/1 2011/1 2010/1 2011/1 2011 201
Team Throughput and	21 22	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Number and proportion of pati Number and proportion of pati	ut and pa	406	63%	7 — F	patie	293	0%		100% 79%	NCPR NCPR NCPR NCCA CWT NLCA NLCA NLCA NLCA NLCA HES	2010/1 2010/1 2010/1 2010/1 2011 2011 20
Team	21 22 23 24 25	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [experticated proportion of pati Proportion of tumours with emergency presentations [experticated proportion of pati Proportion	ut and pa	1 406 thol	Ogy 47%	7 — F	Datie 54%	293 ent	0 Ore	eakdown	100% 79%	NCPR NCPR NLCA CWT NLCA NLCA NLCA NLCA NLCA HES	2010/1 2010/1 2011/1 2010/1 2011 2011 20
Team Throughput and	21 22 23 24 25 26	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [experticated proportion of pati Proportion of tumours with emergency presentations [experticated proportion of pati Proportion	ut and pa	1 406 thol	Ogy 47%	7 — F	Datie 54%	293 ent	0 Ore	eakdown	100% 79%	NCPR NCPR NCPR NCCA CWT NLCA NLCA NLCA NLCA NLCA HES	2010/1 2010/1 2011/1 2010/1 2011/1 2011 201
Team Throughput and pathology	21 22 23 24 25 26	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Sumber and proportion of pati Estimated proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency pre	ut and pa	1 406 thol	Ogy 47%	7 — F	Datie 54%	293 ent	0 Ore	eakdown	100% 79%	NCPR NCPR NCPR NLCA CWT NLCA NLCA NLCA NLCA NLCA HES CWT CWT	2010/1 2010/1 2011/1 2011/1 2011 2011 20
Team Throughput and pathology	21 22 23 24 25 26	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [experticated proportion of pati Proportion of tumours with emergency presentations [experticated proportion of pati Proportion	ut and pa	1 406 thol	Ogy 47%	7 — F	Datie 54%	293 ent	0 Ore	eakdown	100% 79%	NCPR NCPR NCPR NLCA CWT NLCA NLCA NLCA NLCA NLCA HES CWT CWT	2010/1 2010/1 2011/1 2011/1 2011 2011 20
Team hroughput and pathology	21 22 23 24 25 26	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper 02 2012/13: Urgent GP referral for suspected cancer seen within 2 w 02 20 Urgen Waiting times pe 02 2012/13: First treatment began witnin 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemother	ut and pa imental eeks rformanc apy and/or radiotherapy	1 406 thol	Ogy 47%	7 — F	Datie 54%	293 ent 37% 6 37% 0n/ 99% 60%	2% 88% de	eakdown	100% 79% 100% 97% 1100%	NCPR NCPR NCPR NL CA NL CA NL CA NL CA NL CA NL CA CWT CWT CWT CWT CWT CWT CWT CWT CWT	2010/1 2010/1 2011/1 2011/1 2011 2011 20
Team Throughput and pathology	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Stimated proportion of tumours with emergency presentations [exper Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 w Q2 20 Urgen Waiting times pe Caset O2 2012/13: First treatment began witnin 31 days or decision to treat No. and proportion of patients (from #2) receiving surgery, chemother No. and proportion resected of patients (from #2) excluding confirmed	ut and pa imental eeks rformanc apy and/or radiotherapy sclc	tholo	Ogy 47% d c	7 — F	Datie 54% 7 ersi	293 ent 37% 37% 97% 60% 60% 16%	2% 88% de 91% 36% 0%	eakdown	100% 79% 1 100% 97% 1100%	NCPR NCPR NCPR NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT CWT CWT NLCA	2010/1 2010/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2012/13 2012/13 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1
Team Throughput and pathology	21 22 23 24 25 26	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 w Q2 20 Urgen Q3 2012/13: First treatment began within 31 days or decision to treat No. and proportion resected of patients (from #2) excluding confirmed No. and proportion resected of patients (from #2) with confirmed NSC	ut and pa imental eeks rformanc apy and/or radiotherapy sclc	tholo	Ogy 47% d c	7 — F	Datie 54% 7 ersi	293 293 291 293 297 297 297 37% 37% 37% 37% 37% 37% 37% 37% 37% 37	2% 88% de 91% 36% 0%	eakdown	100% 79% 1 100% 97% 1100% 1100% 38% 45%	NCPR NCPR NCPR NCPR NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2010/1 2010/1 2011/1 2011 2011 20
Team hroughput and pathology	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper G2 2012/13: Urgent GP referral for suspected cancer seen within 2 w Q2 20 Urgen Cases Q2 2012/13: First treatment began within 31 days or decision to treat No. and proportion of patients (from #2) receiving surgery, chemother No. and proportion resected of patients (from #2) excluding confirmed NSC No. and proportion resected of patients (from #2), excluding confirmed NSC No. and proportion resected of patients (from #2), excluding confirmed NSC No. and proportion resected of patients (from #2), excluding confirmed SSC	ut and pa imental eeks rformanc apy and/or radiotherapy ISCLC LC LC LC, with stage I and I	1 406 thol	Ogy 47% d c	7 — F	Datie 54% 7 ersi	293 293 293 291 297 37% 37% 37% 6 60% 6 60% 6 21% 6 53%	2% 88% de 91% 36% 0% 0%	eakdown	100% 79% 100% 97% 1100% 1100% 38% 45% 100%	NCPR NCPR NCPR NLCA NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA	2010/1 2010/1 2010/1 2011/1
Team hroughput and bathology	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 w Q2 20 Urgen Q3 2012/13: First treatment began within 31 days or decision to treat No. and proportion resected of patients (from #2) excluding confirmed No. and proportion resected of patients (from #2) with confirmed NSC	ut and pa imental eeks rformanc apy and/or radiotherapy ISCLC LC LC LC, with stage I and I	tholo	Ogy 47% d c	7 — F	Datie 54% 7 ersi	293 293 291 293 297 297 297 37% 37% 37% 37% 37% 37% 37% 37% 37% 37	2% 88% de 91% 36% 0%	eakdown	100% 79% 1 100% 97% 1100% 1100% 38% 45%	NCPR NCPR NCPR NCPR NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2010/1 2011/1
Team hroughput and bathology	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper 02 2012/13: Urgent GP referral for suspected cancer seen within 2 w 02 20 Urgen Waiting times pe 02 2012/13: Pirst treatment began within 31 days of decision to treat No. and proportion of patients (from #2) excluding confirmed No. and proportion resected of patients (from #2) excluding confirmed No. and proportion resected of patients (from #2) excluding confirmed SCL No. and proportion of patients (from #2), excluding confirmed SCL No. and proportion of patients (from #2) with confirmed SCL No. and proportion of patients (from #2) with confirmed SCL No. and proportion of patients (from #2) with confirmed SCLC receiving the patients (from #2) with confirmed SCL	ut and pa imental eeks rformanc apy and/or radiotherapy ISCLC LC LC LC, with stage I and I	tholo	Ogy 47% d c	7 — F	Datie 54% 7 ersi	293 293 293 291 297 37% 37% 37% 6 60% 6 60% 6 21% 6 53%	2% 88% de 91% 36% 0% 0%	eakdown tection rates	100% 79% 100% 97% 1100% 1100% 38% 45% 100% 100%	NCPR NCPR NCPR NCPR NLCA NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2010/1 2011/1 2011/1 2011 2011 20
Team hroughput and pathology saiting times Practice	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper 102 2012/13: Urgent GP referral for suspected cancer seen within 2 w 102 20 Urgen Cases 102 2012/13: First treatment began within 31 days or decision to treat 103 and proportion of patients (from #2) receiving surgery, chemother 104 No. and proportion resected of patients (from #2) excluding confirmed NSC 105 No. and proportion resected of patients (from #2), excluding confirmed SCI. 106 No. and proportion of patients (from #2) with confirmed SCI. 107 No. and proportion of patients (from #2) with confirmed SCI. 108 No. and proportion of patients (from #2) with confirmed SCI. 109 No. and proportion of patients (from #2) with confirmed SCI. 109 No. and proportion of patients (from #2) with confirmed SCI. 109 No. and proportion of patients (from #2) with confirmed SCI. 109 No. and proportion of patients (from #2) with confirmed SCI. 100 No. and proportion of patients (from #2) with confirmed SCI. 100 No. and proportion of patients (from #2) with confirmed SCI. 100 No. and proportion of patients (from #2) with confirmed SCI. 100 No. and proportion of patients (from #2) with confirmed SCI.	ut and pa imental] eeks rformanc apy and/or radiotherapy ISCLC LC LC, with stage I and I g chemotherapy	tholo	9gy 47% d c	7 - p	patie	293 293 293 297 298 37% 000/ 500/ 500/ 500/ 500/ 500/ 500/ 500	2% 88% de 91% 36% 0% 0%	eakdown	100% 79% 100% 97% 1100% 1100% 38% 45% 100% 45% 100%	NCPR NCPR NCPR NCPR NLCA NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2010/1 2011/1 2011/1 2011 2011 20
Team nroughput and vathology aiting times	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Number and proportion of pati Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper G2 2012/13: Urgent GP referral for suspected cancer seen within 2 w Q2 20 Urgen Cases Q2 2012/13: First treatment began within 31 days or decision to treat No. and proportion of patients (from #2) receiving surgery, chemother No. and proportion resected of patients (from #2) excluding confirmed No. and proportion resected of patients (from #2), excluding confirmed NSC No. and proportion of patients (from #2), excluding confirmed SCL No. and proportion of patients (from #2), excluding confirmed SCL No. and proportion of patients (from #2) with confirmed SCL First outpatient appointments and proportion of all outpatient appoin NLCA: Median survival in days and adjusted hazard ratio for morta	ut and pa imental eeks rformanc apy and/or radiotherapy ISCLC LC LC LC, with stage I and I	tholo	9gy 47% d c	7 - p	patie	293 293 293 297 298 37% 000/ 500/ 500/ 500/ 500/ 500/ 500/ 500	2% 88% de 91% 36% 0% 0%	eakdown tection rates	100% 79% 100% 97% 1100% 1100% 38% 45% 100% 100%	NCPR NCPR NI CA	2010/1 2010/1 2011/1
Team Troughput and pathology aiting times Practice Outcomes dd Recovery	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 w Q2 20 Urgen Cases Q2 2012/13: First treatment began within 31 days or decision to treat No. and proportion of patients (from #2) receiving surgery, chemother No. and proportion resected of patients (from #2) with confirmed NSC No. and proportion resected of patients (from #2), excluding confirmed SC No. and proportion resected of patients (from #2), excluding confirmed SC No. and proportion of patients (from #2) with confirmed SCLC receiving surgery, characteristic patients (from #2) with confirmed SCLC receiving surgery (from #2) with confi	ut and pa imental] eeks rformanc apy and/or radiotherapy SCLC LC LC LC, with stage I and Ig chemotherapy Coutcome	tholo	9gy 47% d c	7 - p	patie	293 293 293 297 298 37% 000/ 500/ 500/ 500/ 500/ 500/ 500/ 500	2% 88% de 91% 0% 0% 0%	eakdown tection rates	100% 79% 100% 97% 100% 100% 38% 45% 100% 100% 45% 100% 100% 100%	NCPR NCPR NCPR NCPR NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2010/1 2010/1 2010/1 2010/1 2010/1 2011/1 2011 201
Team Throughput and pathology aiting times	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Number and proportion of pati Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper G2 2012/13: Urgent GP referral for suspected cancer seen within 2 w Q2 20 Urgen Cases Q2 2012/13: First treatment began within 31 days or decision to treat No. and proportion of patients (from #2) receiving surgery, chemother No. and proportion resected of patients (from #2) excluding confirmed No. and proportion resected of patients (from #2), excluding confirmed NSC No. and proportion of patients (from #2), excluding confirmed SCL No. and proportion of patients (from #2), excluding confirmed SCL No. and proportion of patients (from #2) with confirmed SCL First outpatient appointments and proportion of all outpatient appoin NLCA: Median survival in days and adjusted hazard ratio for morta	ut and pa imental eeks rformanc apy and/or radiotherapy SCLC LC .C. with stage I and I g chemotherapy Outcome dignity (6) Dation	thologoup the state of the stat	Ogy 47% d c	7 - F 40% Onv 1 - 167% 47% acti	patie standard standa	293 293 293 297 298 37% 000/ 500/ 500/ 500/ 500/ 500/ 500/ 500	2% 88% de 91% 36% 0% 0%	eakdown tection rates	100% 79% 100% 97% 100% 100% 38% 45% 100% 100% 68% 1.49	NCPR NCPR NI CA	2010/11 2011 2011 2011 2011 2011 2011 20

Profiles – detail (1)



Section	#	Indicator
	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)
Size	2	Number of NLCA patients - lung cancer
	3	Number of NLCA patients - mesothelioma
	4	Patients (from #1) aged 70+
6	5	Patients (from #1) with recorded ethnicity
s 2010)	6	Patients (from #5) with recorded ethnicity which is not White-British
phics newly ents, 2	7	Patients (from #1) who are Income Deprived (2)
graphic I on newly patients,	8	Male patients (from #1)
	9	Number and proportion of patients (from #2) with a stage assigned
em basi ose	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned
Demo (based diagnosed	11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned
₽	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned
	13	Proportion of patients (from #2) with a Performance Status assigned

Profiles – detail (2)



	14	Peer review: Does the specialist team have full membership? (3)
Oncololist	15	Peer review: Proportion of peer review indicators met
Specialist Team	16	Peer review: are there immediate risks? (4)
realii	17	Peer review: are there serious concerns? (4)
	18	Number and proportion of patients (from #2) seen by CNS (5)
	19	Number of urgent GP referrals for suspected cancer
	20	Number and proportion of patients (from #2) with confirmed NSCLC
Throughput	21	Number and proportion of patients (from #2) with confirmed SCLC
and pathology	22	Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS
pathology	23	Number and proportion of patients (from #2) with histological confirmation of diagnosis
	24	Estimated proportion of tumours with emergency presentations [experimental]

Profiles – detail (3)



	25	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks
	26	Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer
Waiting times	27	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]
	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]
	29	Q2 2012/13: First treatment began within 31 days of decision to treat
	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC
Practice	32	No. and proportion resected of patients (from #2) with confirmed NSCLC
Practice	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC ,with stage I and II disease
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy
	35	No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy

Profiles – detail (4)



Γ	0	36	First outpatient appointments and proportion of all outpatient appointments	
l,	Outcomes and Recovery	37	NLCA: Median survival in days and adjusted hazard ratio for mortality NLCA: Proportion of patients surviving at one year and adjusted odds ratio of survivi	
٥	and Recovery	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of survivi	ing 1 year
Γ	Patient	39	Patients surveyed & % reporting always being treated with respect & dignity (6)	
l	Experience -	40	Number of survey questions and % of those questions scoring red and green (7)	% Red
	CPES (8)	41	indiffiber of survey questions and % of those questions scoring red and green (7)	% Green

Profiles development



2013/2014

- Existing profiles converted to web format Sept 2013
- 4 further service profiles released (OG, Sarcoma,
 Gynaecology, Head & Neck) Sept 2013
- CCG profiles released Dec 2013

Profiles development



2014/2015

- Develop 4 further service profiles (Urology, Haematology, Skin, CNS) – Sept 2014
- Headline narrative reports 2014

Further thoughts



Over to you